StockNews.com Initiates Coverage on Check-Cap (NASDAQ:CHEK)

Stock analysts at StockNews.com assumed coverage on shares of Check-Cap (NASDAQ:CHEK) in a research note issued to investors on Tuesday. The brokerage set a “sell” rating on the medical research company’s stock.

Check-Cap Stock Performance

NASDAQ CHEK opened at $0.82 on Tuesday. The company has a market capitalization of $4.80 million, a PE ratio of -0.27 and a beta of 0.39. The company has a 50-day simple moving average of $1.15 and a 200 day simple moving average of $1.71. Check-Cap has a 52-week low of $0.76 and a 52-week high of $3.45.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.